Addiction Clinical Trial
Official title:
Randomized Double-blind Clinical Trial to Evaluate the Effectiveness of Transcranial Direct Current Stimulation (tDCS) on Internet Game Addiction
Verified date | March 2020 |
Source | Seoul National University Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
In this study, the investigators aimed to investigate the effect of transcranial direct current stimulation (tDCS) on clinical status of Internet game addiction. The clinical status of Internet game addiction includes severity of addiction symptom, subjective craving for gaming, response inhibition and cue reactivity. The investigators hypothesized that real stimulation with tDCS on the dorsolateral prefrontal cortex will have higher effectiveness on severity of addiction symptom, subjective craving for gaming, response inhibition and cue reactivity rather than sham stimulation with tDCS.
Status | Completed |
Enrollment | 31 |
Est. completion date | October 8, 2019 |
Est. primary completion date | September 1, 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 50 Years |
Eligibility |
Inclusion Criteria: - Diagnosis of Internet gaming disorder based on diagnostic criteria of Diagnostic and Statistical Manual of Mental Disorders (DSM)-5. Exclusion Criteria: - History of seizure - History of significant head injury - Mental retardation - Schizophrenia - History of stroke |
Country | Name | City | State |
---|---|---|---|
Korea, Republic of | SMG-SNU Boramae Medical Center | Seoul |
Lead Sponsor | Collaborator |
---|---|
Seoul National University Hospital | National Research Foundation of Korea, SMG-SNU Boramae Medical Center |
Korea, Republic of,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Young Internet Addiction Test (Y-IAT) | The Y-IAT is rated on a five-point scale. Total scores for all 20 items range from 20 to 100. | baseline | |
Primary | Young Internet Addiction Test (Y-IAT) | The Y-IAT is rated on a five-point scale. Total scores for all 20 items range from 20 to 100. | 1 week | |
Primary | Young Internet Addiction Test (Y-IAT) | The Y-IAT is rated on a five-point scale. Total scores for all 20 items range from 20 to 100. | 5 week | |
Primary | Young Internet Addiction Test (Y-IAT) | The Y-IAT is rated on a five-point scale. Total scores for all 20 items range from 20 to 100. | 25 week | |
Secondary | Direction error and successful stop ratio in the Stop signal task | The stop signal task is a neurocognitive task for assessing response inhibition. | baseline, 5 weeks, 25 weeks | |
Secondary | Barratt impulsiveness scale-11 | Barratt impulsiveness scale-11 is a self-report questionnaire consisting of 30 items. Each question has a 4-point scale ranging from 1 (rarely/never) to 4 (almost always/always). This scale scores three subscales: attentional impulsiveness, motor impulsiveness, and nonplanning impulsiveness. The total score ranges from 30 to 120 and higher scores indicate greater impulsivity. | baseline, 5 weeks, 25 weeks | |
Secondary | Anti-saccade error rate in the attentional bias task | The attentional bias task is measured by anti-saccade task using eye-tracking analysis for assessing attentional bias on Internet gaming stimuli. | baseline, 5 weeks, 25 weeks | |
Secondary | Late positive potential in the cue reactivity event-related potential | Event-related potential measures with cue reactivity task | baseline, 5 weeks, 25 weeks | |
Secondary | Visual analogue scale | Subjective craving for Internet gaming ranging from 0 to 10. Higher score represents higher craving for gaming. | baseline, 1 week, 5 weeks, 25 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT03576768 -
QuitFast: Evaluating Transcranial Magnetic Stimulation as a Tool to Reduce Smoking Directly Following a Quit Attempt
|
N/A | |
Completed |
NCT04110626 -
Realistic Evaluation of Expériences Animées, a School-based Intervention in Nouvelle Aquitaine
|
||
Completed |
NCT03007940 -
Using NIATx Strategies to Implement Integrated Services in Routine Care
|
N/A | |
Not yet recruiting |
NCT04030858 -
The INFINITE Study: A Prospective Investigation of a Nutrient-dense Diet in Early Addiction Recovery
|
N/A | |
Active, not recruiting |
NCT02836080 -
Integrated Collaborative Care Teams for Youth With Mental Health and/or Addiction Challenges (YouthCan IMPACT)
|
N/A | |
Completed |
NCT03221985 -
ESM Pilot: Mobile Phones and Psychology
|
N/A | |
Completed |
NCT02556060 -
Lamotrigine for Ketamine Dependence Trial
|
Phase 2/Phase 3 | |
Completed |
NCT02812810 -
Evaluation of the Efficacy of Repetitive Transcranial Magnetic Stimulation (rTMS) Low-frequency on Craving in Smoking Dependence
|
N/A | |
Completed |
NCT01531153 -
Cognitive Enhancement as a Target for Cocaine Pharmacotherapy
|
N/A | |
Recruiting |
NCT05976646 -
Phase Ib/2a Drug-drug Interaction Study of a Combination of 45mg Dextromethorphan With 105 mg Bupropion
|
Phase 1/Phase 2 | |
Completed |
NCT04409106 -
The Turkish Version of the Parental Smartphone Use Management Scale (PSUMS)
|
||
Not yet recruiting |
NCT06459609 -
Effect of Protein Supplementation on Craving in Subjects Hospitalised for Addiction Treatment
|
N/A | |
Recruiting |
NCT05595759 -
Violence Against Women in Patients With Alcohol Substance Addiction Training
|
N/A | |
Completed |
NCT04099173 -
A Brief Mindfulness-Based Intervention for Suicidal Ideation
|
N/A | |
Recruiting |
NCT04959643 -
Systematic Screening for Viral Hepatitis B and C at the PASS Consultation of the Montpellier University Hospital
|
||
Completed |
NCT04133688 -
Mobile App in Addiction
|
N/A | |
Recruiting |
NCT04063267 -
Electronic Cigarettes as a Harm Reduction Strategy in Individuals With Substance Use Disorder
|
Phase 2 | |
Completed |
NCT05114577 -
Recovery Sleepers: A Pilot Study of a Sleep Health Intervention for College Students in Recovery
|
N/A | |
Terminated |
NCT02671240 -
Prognosis of Behavioral Addiction in Parkinson's Disease
|
||
Not yet recruiting |
NCT03813095 -
Exploratory Dose Ranging Study Assessing APH-1501 for the Treatment of Opioid Addiction
|
Phase 2 |